Cellebrite DI Ltd. (NASDAQ:CLBT) Shares Sold by Portolan Capital Management LLC

Portolan Capital Management LLC reduced its stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 25.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 914,856 shares of the company's stock after selling 309,164 shares during the period. Cellebrite DI accounts for about 1.4% of Portolan Capital Management LLC's holdings, making the stock its 21st biggest position. Portolan Capital Management LLC owned 0.44% of Cellebrite DI worth $20,154,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of the stock. Barclays PLC lifted its position in Cellebrite DI by 69.1% in the fourth quarter. Barclays PLC now owns 445,795 shares of the company's stock valued at $9,821,000 after acquiring an additional 182,138 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Cellebrite DI by 7.7% during the fourth quarter. Renaissance Technologies LLC now owns 1,630,439 shares of the company's stock worth $35,919,000 after purchasing an additional 115,939 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Cellebrite DI by 30.0% in the 4th quarter. Legal & General Group Plc now owns 160,223 shares of the company's stock valued at $3,530,000 after purchasing an additional 36,949 shares during the last quarter. Invesco Ltd. acquired a new stake in shares of Cellebrite DI in the 4th quarter valued at about $32,700,000. Finally, FMR LLC grew its stake in Cellebrite DI by 89.1% during the 4th quarter. FMR LLC now owns 10,621,344 shares of the company's stock worth $233,988,000 after buying an additional 5,004,587 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on CLBT shares. Needham & Company LLC reissued a "buy" rating and set a $28.00 price objective on shares of Cellebrite DI in a research report on Wednesday, April 2nd. JPMorgan Chase & Co. boosted their price target on Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Finally, Lake Street Capital increased their price objective on Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $23.43.

Cellebrite DI Trading Down 0.7 %

Shares of CLBT traded down $0.13 during mid-day trading on Friday, hitting $18.90. The company's stock had a trading volume of 886,090 shares, compared to its average volume of 1,406,673. The firm has a 50-day simple moving average of $18.99 and a 200 day simple moving average of $20.05. Cellebrite DI Ltd. has a 1-year low of $10.25 and a 1-year high of $26.30. The firm has a market capitalization of $4.53 billion, a P/E ratio of -13.60, a P/E/G ratio of 4.27 and a beta of 1.44.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. As a group, sell-side analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.